Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cancer Risk Assessment Using 5-ALA for Urological and Gastrointestinal Cancers
jRCTs061220051Completed
- Sponsor
- SBI Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of 5-aminolevulinic acid in prostate cancer (PCa), bladder cancer, renal cell carcinoma (RCC) and 1 more (2 arms), sponsored by SBI Pharmaceuticals. Primary endpoint: Primary diagnostic performance of simple urinary coproporphyrin assay. Started Aug 2022; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
prostate cancer (PCa)bladder cancerrenal cell carcinoma (RCC)colon cancer
Beyond the preview
Go deeper on jRCTs061220051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061220051.